Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cultured glioma cells
- 1 November 1992
- journal article
- laboratory investigation
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 14 (3) , 213-223
- https://doi.org/10.1007/bf00172597
Abstract
Epidermal growth factor, EGF, and 131I or 125I-labelled tyrosine were conjugated to the sugar polymere dextran. The conjugates bound to EGF-receptor rich human glioma cells in culture and the binding was mainly receptor specific because cells presaturated with nonradioactive EGF gave strongly reduced binding. The 131I labelled conjugates were used in tests on cellular retention and therapeutical effects. 131I activity delivered to the cells as EGF-dextran-tyrosine-131I remained cell-associated for much longer periods of time than 131I activity delivered by only EGF. The amount of cell-associated 131I activity was nearly constant for up to 25 hours. The 131I labelled conjugate gave, after a one hour incubation period for binding followed by a 25 hour incubation in nonradioactive medium, a good therapeutical effect. This effect, which corresponded to about 3.0 Gy of external 60Co radiation, was due to the specifically bound 131I, The comparatively small effects of nonbound 131I in the culture medium, present only during the first incubation hour, were measured in control experiments with presaturated receptors and were corrected for in the evaluation of the EGF-receptor mediated effects. Control experiments showed that neither nonradioactive EGF nor non-radioactive EGF-dextran conjugates gave measurable effects on clonogenic growth. The results obtained were promising and the possibilities to use EGF-dextran conjugates for therapy should be further examined.Keywords
This publication has 37 references indexed in Scilit:
- Distribution and stability in the rat of a 76Br/125I-labelled polypeptide, epidermal growth factorInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
- Structural basis for epidermal growth factor receptor functionProgress in Growth Factor Research, 1989
- The solution structures of epidermal growth factor and transforming growth factor alphaProgress in Growth Factor Research, 1989
- Homogeneous penetration but heterogeneous binding of antibodies to carcinoembryonic antigen in human colon carcinoma HT-29 spheroidsCancer Immunology, Immunotherapy, 1989
- Toxicity of ligand and antibody‐directed ricin A‐chain conjugates recognizing the epidermal growth factor receptorJournal of Cellular Physiology, 1987
- Effect of dextran and dextran modifications on the thermal and proteolytic stability of conjugated bovine testis β-galactosidase and human serum albuminBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1983
- Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cellsJournal of Neuroscience Research, 1982
- Epidermal growth factor-toxin A chain conjugates: EGF-Ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxicCell, 1980
- Preparation and properties of a soluble trypsin-dextran conjugateCellular and Molecular Life Sciences, 1975
- THE USE OF DEXTRAN IN THE TREATMENT OF BLOOD LOSS AND SHOCKThe Lancet Healthy Longevity, 1952